XML 43 R24.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaboration Agreements (Tables) | 12 Months Ended
--- | ---
Dec. 28, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Schedule of Collaborative Revenues Under Collaboration Agreement | Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):
| Year Ended December 31,
| 2018 |  | 2017 |  | 2016
Ipsen collaboration revenues | $ | 182,879 |  |  | $ | 69,792 |  |  | $ | 33,252 |
Collaboration revenues under the collaboration agreement with Merck were as follows (in thousands):
| Year Ended December 31,
| 2018 |  | 2017 |  | 2016
Merck collaboration revenues | $ | — |  |  | $ | — |  |  | $ | 5,000 |
Profits and losses on U.S. commercialization and Royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):
| Year Ended December 31,
| 2018 |  | 2017 |  | 2016
Profits and losses on U.S. commercialization | $ | 8,084 |  |  | $ | (2,140 | ) |  | $ | 8,771 |
Royalty revenues on ex-U.S. sales | $ | 5,564 |  |  | $ | 6,398 |  |  | $ | 2,827 |
Collaboration revenues under the ROR collaboration agreement with BMS were as follows (in thousands):
| Year Ended December 31,
| 2018 |  | 2017 |  | 2016
BMS collaboration revenues | $ | — |  |  | $ | 12,500 |  |  | $ | — |
Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):
| Year Ended December 31,
| 2018 |  | 2017 |  | 2016
Daiichi Sankyo collaboration revenues | $ | 20,000 |  |  | $ | — |  |  | $ | 15,000 |
Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):
| Year Ended December 31,
| 2018 |  | 2017
Takeda collaboration revenues | $ | 18,020 |  |  | $ | 14,779 |
Such royalties were as follows (in thousands):
| Year Ended December 31,
| 2018 |  | 2017 |  | 2016
Royalties accruing to GSK | $ | 23,950 |  |  | $ | 12,413 |  |  | $ | 4,334 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration